Germany's new early benefit assessment for innovative pharmaceuticals
This article was originally published in SRA
Jörg Schickert and Andreas Schmitz bring clarity to some of the pressing questions surrounding the new system of assessment that replaced free drug pricing. There is confusion over the scope of the assessment, dossier obligations and the determination of the comparable therapy.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.